Press release
1 oktober 2015
OVERWHELMING INTEREST FOR SERENDEX SYMPOSIUM
Tuesday evening this week, Serendex hosted a scientific symposium at the international ERS
congress in Amsterdam. The event attracted so many people that congress officials had to
close the doors causing people to queue up outside the room.
The symposium focused on pulmonary alveolar proteinosis (PAP) and severe pulmonary
infections as well as the role of GM-CSF as immune modulator. The symposium presented
expert speakers from Germany (Prof. Dr. Herold) and Japan (Prof. Dr. Inoue) and was chaired
by Dr. Bonella from Essen in Germany, whose scientific focus is rare lung diseases.
Being an ultra rare disease, PAP traditionally does not attract much attention in the
international respiratory community. However, Serendex’s symposium was packed by
scientific professionals seeking updates and knowledge about PAP and GM-CSF. The
symposium took place in a room intended for 60 participants. The congress officials shut the
doors at 75 participants and still people queued up outside.
”The level of attention was obviously a positive surprise for Serendex and we are thrilled that
our first ever symposium turned out to be such a success. It indicates that there is a real need
in the international scientific PAP community to connect and share scientific updates, views
and experiences”, says Dr. Kim Arvid Nielsen, CEO of Serendex.
Among the participants were professionals from non European countries including Japan,
Russia, Canada and Iran as well as a number of European countries including Italy, Germany,
France and Switzerland.
The symposium was in line with Serendex’s strategy to increase interaction with the scientific
community in order to raise awareness about PAP and to position Serendex on the
international scientific scene for PAP and GM-CSF for inhalation.
Serendex expects to be able to commence a pivotal phase II/III clinical study of GM-CSF for
inhalation for the treatment of PAP in 2016.
For further information please contact:
Nadia Vega Vasiljev
Mobile +45 2014 9615
E-mail: nvv@serendex.com
About Serendex Pharmaceuticals A/S
Serendex Pharmaceuticals develops drugs to treat severe respiratory conditions such as PAP
(pulmonary alveolar proteinosis), BE (bronchiectasis), CF (cystic fibrosis related lung infections)
and DAH (diffuse alveolar hemorrhage). These conditions are acute or chronic and have no
existing medical treatment. All Serendex drugs are inhaled or induced to the lungs of the
patient. This improves the risk/efficacy ratio of the drug and treatment. Serendex has obtained
orphan drug designation (ODD) for several indications in both Europe and USA. The company’s
Serendex Pharmaceuticals A/S // www.serendex.com // info@serendex.com // Slotsmarken 17, 2.tv, DK-2970
Hørsholm
sole business focus is drug repositioning, i.e. finding new indications and administration routes
for existing drugs. Serendex Pharmaceuticals is listed at Oslo Axess. Please visit
www.serendex.com to learn more.